Moderna (WBO:MRNA) Short-Term Capital Lease Obligation : €23 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Moderna Short-Term Capital Lease Obligation?

Moderna's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €23 Mil.

Moderna's quarterly Short-Term Capital Lease Obligation declined from Sep. 2023 (€171 Mil) to Dec. 2023 (€23 Mil) but then increased from Dec. 2023 (€23 Mil) to Mar. 2024 (€23 Mil).

Moderna's annual Short-Term Capital Lease Obligation declined from Dec. 2021 (€187 Mil) to Dec. 2022 (€185 Mil) and declined from Dec. 2022 (€185 Mil) to Dec. 2023 (€23 Mil).

Moderna Short-Term Capital Lease Obligation Historical Data

The historical data trend for Moderna's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Short-Term Capital Lease Obligation Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

24.66

186.74

185.02

22.93

Moderna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															169.05	203.98	171.47	22.93	23.00

Moderna Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Moderna Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Moderna's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (WBO:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (WBO:MRNA) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.